Feedback
Settings

Settings

Goto Application

1. CL2014000181 - VERSIONES HUMANIZADAS DE EL ANTICUERPO MURINO 224G11 QUE INHIBEN LA DIMERIZACIÓN DEL FACTOR DE CRECIMIENTO DE HEPACTOCITOS (C-MET) Y QUE NO TIENEN ACTIVIDAD AGONISTA INTRINSECA; ACIDOS NUCLEICOS; VECTORES; CELULA HUESPED; PROCESO DE PRODUCCIÓN; COMPOSICIONES; USOS Y MÉTODOS PARA TRATAR EL CÁNCER. (DIVISIONAL SOLICITUD 1296-2011)

PermaLink
Office
Chile
Application Number 2014000181
Application Date 24.01.2014
Publication Number 2014000181
Publication Date 25.07.2014
Publication Kind A1
IPC
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K 16/2863
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2863against receptors for growth factors, growth regulators
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/53
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
52Constant or Fc region; Isotype
53Hinge
C07K 2317/56
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
Applicants PIERRE FABRE MEDICAMENT
Inventors GOETSH LILIANE
WURCH THIERRY
BES CEDRIC
Agents Estudio Sargent & Krahn
Priority Data IB2008/055663 02.12.2008 EM
61/184.502 05.06.2009 US
Title
(ES) VERSIONES HUMANIZADAS DE EL ANTICUERPO MURINO 224G11 QUE INHIBEN LA DIMERIZACIÓN DEL FACTOR DE CRECIMIENTO DE HEPACTOCITOS (C-MET) Y QUE NO TIENEN ACTIVIDAD AGONISTA INTRINSECA; ACIDOS NUCLEICOS; VECTORES; CELULA HUESPED; PROCESO DE PRODUCCIÓN; COMPOSICIONES; USOS Y MÉTODOS PARA TRATAR EL CÁNCER. (DIVISIONAL SOLICITUD 1296-2011)
Abstract
(ES) La invención se refiere a un anticuerpo novedoso capaz de unirse específicamente al receptor c-Met humano y/o capaz de inhibir específicamente la actividad de tirosina quinasa de dicho receptor, con una actividad antagonista mejorada, comprendiendo dicho anticuerpo una región bisagra modificada. La invención se refiere además a una composición que comprende ese tipo de anticuerpo antagonista de c-Met y su uso como medicamento para tratar el cáncer.
Related patent documents
WO/2010/064089
PT2370468
DK3135691
SG187518
CN103351438
RU2015127471
EP3431502
LT2370468
LT3135691
ES2697098
PT3135691
RS58018
EP2370468
SG171851
US20110239316
PE2012-0343
CN102227446
RU2011124751
CA2743433
KR1020110097839
RU0002560257
BRPI0923231
EP3135691
AU2009328318
VN29032
VN36594
ID051.4535
MYPI 2011002426
PH1/2015/501515
ES2629855
JP2012510280
RS56204
PH1/2011/500928
VN1201704713
WO/2010/069765
PT3431502
EP3757132
BR122019023930
ES2827277
PL3431502
PL2370468
PL3135691
TN2011000216
MX2011005677
MXMX/a/2011/005677
IL213273
CL2011001296
IN4332/DELNP/2011
MA32892
CR145/20110324
CRCR2011-000324This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
CO6382139
CO13128289This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
NZ593853
GE12279This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
GE12279/1This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
UAa201108288This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
RU2011124751This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
US20130109840
US20130109844
US20130109841
GE12919/1This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
GE12919This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
IL231525
US20160159911
JP2016117721
AU2016200725
US20170218071
JP2017099392
AU2017203929
US20180142024
US20190359717
US20210087278
MYPI 2020006937
# -